Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Tegafur Gimeracil Oteracil in 3L mCRC
NCT06255379Phase 2Not yet recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Guangzhou University of Chinese Medicine. Planned start May 2024; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06255379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255379.